This test is used to detect resistance variants in the ABL1 kinase domain of CML/ALL patients (BCR::ABL1 at diagnosis) who have a lack/loss of response to tryosine kinase inhibitor (TKI) therapy, a rising BCR::ABL1 transcript level or loss of major molecular response (>0.1 % BCR::ABL1 to ABL1 control gene).
Genetics - Molecular Oncology
3x EDTA (Lavender) dedicated to Genetics
Send to MONC
12 ml peripheral blood in EDTA. 1-3 ml of bone marrow in EDTA or RPMI (anticoagulant).
Transport to the laboratory at ambient temperature within 48 hours of collection to ensure high-quality RNA can be extracted.
Clinically significant variants in the ABL1 kinase domain of the BCR::ABL1 transcript are reported.
RNA extraction/storage and Sanger Sequencing of semi-nested PCR products containing the ABL1 kinase domain of the BCR::ABL1 transcript.
Variants with an allele frequency less than 20% may not be detected by this method.
$650.39 (Exclusive of GST)
An additional charge of approximately $200 may be applied to samples received on weekends and public holidays for extraction of RNA by on-call staff.